APOBEC3G and APOBEC3F rarely co-mutate the same HIV genome

Retrovirology

Volumn 9, Issue , 2012, Pages

  Ebrahimi, Diako ^a   Anwar, Firoz ^a   Davenport, Miles P ^a  

^a UNIVERSITY OF NEW SOUTH WALES   (Australia)

Author keywords

APOBEC3F; APOBEC3G; G to A mutation signature; Hypermutated HIV; Motif representation

Indexed keywords

APOLIPOPROTEIN B MESSENGER RNA EDITING ENZYME CATALYTIC POLYPEPTIDE 3F; APOLIPOPROTEIN B MESSENGER RNA EDITING ENZYME CATALYTIC POLYPEPTIDE 3G;

ARTICLE; CONSENSUS SEQUENCE; CONTROLLED STUDY; GENE IDENTIFICATION; GENE MUTATION; GENE SEQUENCE; GENE TARGETING; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; NONHUMAN; NUCLEOTIDE SEQUENCE; PROTEIN FOOTPRINTING; PROTEIN MOTIF; VIRUS GENOME;

CYTIDINE DEAMINASE; CYTOSINE DEAMINASE; GENOME, VIRAL; HIV-1; HUMANS; MUTATION; NUCLEOTIDE MOTIFS;

HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 84871202625     PISSN: None     EISSN: 17424690     Source Type: Journal    
DOI: 10.1186/1742-4690-9-113     Document Type: Article

References (25)

1. Harris RS, Liddament MT. Retroviral restriction by APOBEC proteins. Nat Rev Immunol 2004, 4:868-877.
2. Sawyer SL, Emerman M, Malik HS. Ancient adaptive evolution of the primate antiviral DNA-editing enzyme APOBEC3G. PLoS Biol 2004, 2:1278-1285.
3. Jager S, Kim DY, Hultquist JF, Shindo K, LaRue RS, Kwon E, Li M, Anderson BD, Yen L, Stanley D, et al. Vif hijacks CBF-beta to degrade APOBEC3G and promote HIV-1 infection. Nature 2012, 481:371-375.
4. Browne EP, Allers C, Landau NR. Restriction of HIV-1 by APOBEC3G is cytidine deaminase-dependent. Virology 2009, 387:313-321.
5. Holmes RK, Malim MH, Bishop KN. APOBEC-mediated viral restriction: not simply editing?. Trends Biochem Sci 2007, 32:118-128.
6. Yu Q, Konig R, Pillai S, Chiles K, Kearney M, Palmer S, Richman D, Coffin JM, Landau NR. Single-strand specificity of APOBEC3G accounts for minus-strand deamination of the HIV genome. Nat Struct Mol Biol 2004, 11:435-442.
7. Armitage AE, Katzourakis A, de Oliveira T, Welch JJ, Belshaw R, Bishop KN, Kramer B, McMichael AJ, Rambaut A, Iversen AK. Conserved footprints of APOBEC3G on Hypermutated human immunodeficiency virus type 1 and human endogenous retrovirus HERV-K(HML2) sequences. J Virol 2008, 82:8743-8761.
8. Kijak GH, Janini LM, Tovanabutra S, Sanders-Buell E, Arroyo MA, Robb ML, Michael NL, Birx DL, McCutchan FE. Variable contexts and levels of hypermutation in HIV-1 proviral genomes recovered from primary peripheral blood mononuclear cells. Virology 2008, 376:101-111.
9. Vartanian JP, Henry M, Wain-Hobson S. Sustained G->A hypermutation during reverse transcription of an entire human immunodeficiency virus type 1 strain Vau group O genome. J Gen Virol 2002, 83:801-805.
10. Wiegand HL, Doehle BP, Bogerd HP, Cullen BR. A second human antiretroviral factor, APOBEC3F, is suppressed by the HIV-1 and HIV-2 Vif proteins. EMBO J 2004, 23:2451-2458.
11. Liddament MT, Brown WL, Schumacher AJ, Harris RS. APOBEC3F properties and hypermutation preferences indicate activity against HIV-1 in vivo. Curr Biol 2004, 14:1385-1391.
12. Wichroski MJ, Robb GB, Rana TM. Human retroviral host restriction factors APOBEC3G and APOBEC3F localize to mRNA processing bodies. PLoS Pathog 2006, 2:374-383.
13. Kieffer TL, Kwon P, Nettles RE, Han YF, Ray SC, Siliciano RF. G -> A hypermutation in protease and reverse transcriptase regions of human immunodeficiency virus type 1 residing in resting CD4(+) T cells in vivo. J Virol 2005, 79:1975-1980.
14. Land AM, Ball TB, Luo M, Pilon R, Sandstrom P, Embree' JE, Wachihi C, Kimani J, Plummer FA. Human immunodeficiency virus (HIV) type 1 proviral hypermutation correlates with CD4 count in HIV-infected women from Kenya. J Virol 2008, 82:8172-8182.
15. Piantadosi A, Humes D, Chohan B, McClelland RS, Overbaugh J. Analysis of the Percentage of Human Immunodeficiency Virus Type 1 Sequences That Are Hypermutated and Markers of Disease Progression in a Longitudinal Cohort, Including One Individual with a Partially Defective Vif. J Virol 2009, 83:7805-7814.
16. Pace C, Keller J, Nolan D, James I, Gaudieri S, Moore C, Mallal S. Population level analysis of human immunodeficiency virus type 1 hypermutation and its relationship with APOBEC3G and vif genetic variation. J Virol 2006, 80:9259-9269.
17. Gandhi SK, Siliciano JD, Bailey JR, Siliciano RF, Blankson JN. Role of APOBEC3G/F-mediated hypermutation in the control of human immunodeficiency virus type 1 in elite suppressors. J Virol 2008, 82:3125-3130.
18. Ulenga NK, Sarr AD, Hamel D, Sankale JL, Mboup S, Kanki PJ. The Level of APOBEC3G (hA3G)-Related G-to-A Mutations Does Not Correlate with Viral Load in HIV Type 1-Infected Individuals. AIDS Res Hum Retroviruses 2008, 24:1285-1290.
19. Sadler HA, Stenglein MD, Harris RS, Mansky LM. APOBEC3G contributes to HIV-1 variation through sublethal mutagenesis. J Virol 2010, 84:7396-7404.
20. Ebrahimi D, Anwar F, Davenport MP. APOBEC3 Has Not Left an Evolutionary Footprint on the HIV-1 Genome. J Virol 2011, 85:9139-9146.
21. Hultquist JF, Lengyel JA, Refsland EW, LaRue RS, Lackey L, Brown WL, Harris RS. Human and Rhesus APOBEC3D, APOBEC3F, APOBEC3G, and APOBEC3H Demonstrate a Conserved Capacity To Restrict Vif-Deficient HIV-1. J Virol 2011, 85:11220-11234.
22. Jern P, Russell RA, Pathak VK, Coffin JM. Likely Role of APOBEC3G-Mediated G-to-A Mutations in HIV-1 Evolution and Drug Resistance. PLoS Pathog 2009, 5:e1000367.
23. Janini M, Rogers M, Birx DR, McCutchan FE. Human immunodeficiency virus type 1 DNA sequences genetically damaged by hypermutation are often abundant in patient peripheral blood mononuclear cells and may be generated during near-simultaneous infection and activation of CD4(+) T cells. J Virol 2001, 75:7973-7986.
24. Xu H, Chertova E, Chen J, Ott DE, Roser JD, Hu WS, Pathak VK. Stoichiometry of the antiviral protein APOBEC3G in HIV-1 virions. Virology 2007, 360:247-256.
25. Brereton RG. One-class classifiers. J Chemometrics 2011, 25:225-246.